Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898684 | 0.91 | CA12 (0.53) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL7399614 | 0.91 | CA12 (0.55) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL3155955 | 0.90 | CA12 (0.53) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL3903773 | 0.89 | CA12 (0.53) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL3195599 | 0.89 | CA12 (0.52) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL17874358 | 0.88 | CA12 (0.53) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL3203569 | 0.86 | CA12 (0.54) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL3161402 | 0.86 | CA12 (0.52) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL17874359 | 0.86 | CA12 (0.55) | CA12CA1CA2CA9 | |
| SCHEMBL3194156 | 0.85 | CA12 (0.48) | CA12CA1CA2CA9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | CA12 2570/4885CA1 2130/4885CA2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.